Ligand Pharmaceuticals, Inc. (LGND) Misses Q3 EPS by 5c

Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q3 EPS of ($0.01), $0.05 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $6.4 million versus the consensus estimate of $8.4 million.

Separately, the company announced it is restating LFY11, Q112, Q212 financials.

For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Optimum Communications gets NYSE non-compliance notice over stock price